111in-daclizumab
mAbexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2002 (NCT00040430)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Peripheral myelin protein 22Radiodepletion
PMP22 radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Also known as
- 111in-daclizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01468311 | Phase 1/Phase 2 (Phase 2) | Oct 11, 2011 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00040560 | Phase 1 | Jun 28, 2002 | Copharos |
| NCT00040430 | Phase 1 | Jun 26, 2002 | Copharos |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Copharos | For profit | 2 | 2 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1